Eficacia Do Tratamento Baseado Em Venetoclax Em Paciente Jovem Com Leucemia Mieloide Aguda Recidivada Candidato a Transplante De Medula Ossea Alogenico

Introducao: A Leucemia Mieloide Aguda (LMA) e uma doenca agressiva, e em geral, de prognostico reservado. O tratamento com intuito curativo e realizado com altas doses de quimioterapia, seguido ou nao por transplante de medula ossea (TMO) alogenico. Porem, a recidiva ainda representa um desafio a ser superado, levando a busca de novas opcoes terapeuticas, como o inibidor de bcl-2, Venetoclax. Objetivo: Relatar o caso de um paciente jovem com LMA recidivada com resposta ao tratamento baseado em Venetoclax, seguido por TMO alogenico. Metodo: Levantamento de dados do prontuario e revisao da literatura. Relato do caso: VSV, sexo masculino, 21 anos, diagnosticado com LMA em 18/02/2020, mielograma com 60,4% blastos, com fenotipo CD45+ intermediario;CD34+;CD13+;CD33 parcial;CD64 parcial;HLA-DR parcial;MPO parcial e cariotipo 46, XY [20]. Sem possibilidade de avaliacao molecular da doenca. O paciente recebeu tratamento de inducao padrao (D3A7) atingindo remissao completa apos um ciclo e seguindo com consolidacao com 3 ciclos de ARA-C 3g/m2 ate maio de 2020 (optou-se por nao realizar o 4ciclo devido a pandemia por COVID19). Apresentava doenca residual minima (DRM) negativa em reavaliacao medular de agosto de 2020, mantendo-se ate junho de 2021, quando apresentou recidiva com 33,8% de blastos em imunofenotipagem de reavaliacao. Internado em julho de 2021 para QT de resgate com FLAG, evoluiu com choque septico e insuficiencia respiratoria, sendo necessario suporte em unidade de terapia intensiva. Apos recuperacao clinica, obteve novamente DRM negativa, sendo encaminhado para TMO alogenico aparentado (irma "full match"). Entretanto, enquanto aguardava o transplante, apresentou nova recidiva (IF com 5,4% de blastos), sendo optado por tratamento com Venetoclax + Azacitidina, com reducao de DRM para 1,5%. Recebeu o segundo ciclo de Venetoclax combinado com citarabina, devido a indisponibilidade da Azacitidina, seguido por DRM negativa. O paciente foi submetido ao TMO alogenico em 31/03/22, com avaliacao medular no D+60 com quimerismo de 100%, mantendo DRM negativa no D+120. Discussao: O uso do inibidor de BCL-2 (Venetoclax), em combinacao com agentes hipometilantes ou doses baixas de citarabina, foi aprovado para pacientes recem-diagnosticados com LMA inelegiveis para quimioterapia intensiva, revolucionando o tratamento da doenca. Publicacoes recentes vem demonstrando novos beneficios dessa associacao, tanto previamente ao TMO (em primeira linha ou com doenca recidivada), como na terapia de resgate para recidiva pos-TMO. Tambem tendo sido evidenciado sucesso terapeutico em faixas etarias menores (incluindo criancas). Esses novos estudos motivaram o uso de terapia baseada em venetoclax nesse paciente jovem, com doenca recidivada, conseguindo atingir e manter DRM negativa. Conclusao: O caso relatado demonstra eficacia do Venetoclax (em combinacao com hipometilante ou citarabina) em promover remissao profunda da doenca, tornando o paciente habil para o transplante e aumentando a probabilidade de sobrevida a longo prazo. Copyright © 2022

Dynamic Capabilities and Innovation to Deal with the Impacts of Covid-19

Objective: to assess the extent to which dynamic and innovative capabilities contribute to companies facing turbulent crisis scenarios such as the covid-19 pandemic. Methods: the research is characterized by a quantitative approach through an online survey and analysis by structural equation modeling (SEM). The study sample consisted of 166 companies. Results: The results showed that in the face of crisis environments (unexpected situations), companies with dynamic capabilities could deal more effectively with impacts in the face of crisis. On the other hand, but less significantly (p<0.10), innovation presents itself as a context of risk enhanced by crisis scenarios. Conclusions: The article theoretically contributes to the relationship between the themes of dynamic capacity, innovation, and impacts of the crisis, through a structural model, in the context of the pandemic generated by covid-19. From a managerial and practical perspective, the research highlights the importance of developing dynamic capabilities to face crises, as well as innovation, in the sense of being ready to face difficult scenarios, showing that companies with developed dynamic capabilities were able to face the crisis more satisfactorily. Finally, through factor analysis in a methodological way, the research refines the relationship between relevant themes (dynamic capacity and innovation) given the empirical-contextual axis (covid-19 crisis).

CONSUMER BEHAVIOR IN THE FITNESS MARKET PHYSICAL X VIRTUAL

The survival of Physical Education professionals, as well as companies in the fitness market, faced with adverse external events imposed abruptly by a new reality resulting from the COVID-19 pandemic, exposed the fragility of commercial relations with their students/clients, implicating incomes and forcing them to reinvent themselves and adapt to new ways of costumer services. Therefore, this article aims to identify the influence of the value perception, reability and necessity of interaction in the intention of consumption in the fitness market in physicals spaces x virtuals. A survey-type study was carried out with 161 gym students/clients. The statistical technique used for Structural Equation Modeling (SEM), through which the conceptual model was tested. The results highlight that perception of consumption in physical stores obtains a positive emotional response to the purchase intention on the part of the costumers, whereas it highly values human interaction, generating feelings of joy, satisfaction and well-being, being so sensitive not only with behavioral price as also to monetary. They indicate a greater perception of quality and confidence in the purchase of services/products in special environments when compared to online sales format, considering necessity of interaction between the student/customer and the Physical Education professional.

Development of an artificial intelligence model to predict venous thromboembolic disease in COVID-19 patients at hospital admission

Background: A lot of attention has been drawn to the identification of predictors of VTE in COVID-19 patients, and an accurate clinical prediction model is still lacking in this context. Aims: To develop a clinical prediction model using artificial intelligence techniques, to predict VTE in COVID-19 patients, using variables easily available upon hospital admission. Methods: This multicenter cohort included consecutive adult patients (≥ 18 years-old) with laboratory-confirmed COVID-19 from 37 Brazilian hospitals from 17 cities, between March and September 2020. Study data were collected from medical records using Research Electronic Data Capture (REDCap) tools. We trained multiple machine learning models on various combinations of structured and non-structured features, calibrated to reflect a probability distribution while predicting the desired clinical outcome. Subsequently, we analyzed the relationship between this model ' s predicted confidence score and the fraction of false negatives in the test sample to devise a splitting point where no false negatives would occur, thus calibrating for sensitivity over specificity. The study was approved by the National Research Ethics Commission waiving off the application of informed consent. Results: The dataset included 6421 patients (median age 61 [P25-75 48-73] years-old, 54.8% men), 4.5% of them developed venous thromboembolic disease. Patient ' s age, sex and comorbidities, as well as their list of household prescription drugs, history of recent surgery and laboratory tests were significant predictors. Given a proper confidence level, our model predicted 100% of the true positive cases while eliminating a significant portion of the true negatives (Figure 1). (Figure Presented) Conclusions: This study suggests that an ensemble of decision rules can effectively predict COVID patients with high risk of VTE. It might be possible to decrease the use of anticoagulants while still treating patients with an appreciable likelihood of thromboembolism.